KOLLER F
Bull World Health Organ. 1962;27(6):659-66.
Although there is no general agreement as to the role that anticoagulants can-or should-play in the prevention and treatment of myocardial infarction, nevertheless their use during the first 6-12 weeks after occlusion of a coronary artery seems to be well established for preventing both venous and cardiac thromboses and consequent embolism and thus lowering the mortality during that period. The data at present available suggest that in the prevention of recurrences of myocardial infarction long-term anticoagulant treatment gives less spectacular but at least encouraging results. Only recently have large-scale investigations been conducted into the prevention of the first infarct by long-term use of anticoagulants in angina pectoris; the results to date appear very promising, particularly in acute coronary insufficiency.While there is a very real danger of haemorrhage during long-term anticoagulant treatment, the author considers that haemorrhage need rarely be severe or fatal provided strict attention is paid to contra-indications (e.g., hypertension) and provided adequate control of the patient is ensured.
尽管对于抗凝剂在心肌梗死的预防和治疗中能够发挥或应该发挥何种作用,尚无普遍共识,但冠状动脉闭塞后的最初6至12周内使用抗凝剂,对于预防静脉血栓和心脏血栓以及随之而来的栓塞,从而降低该时期的死亡率,似乎已得到充分认可。目前可得的数据表明,在预防心肌梗死复发方面,长期抗凝治疗虽效果不那么显著,但至少令人鼓舞。直到最近,才针对长期使用抗凝剂预防心绞痛患者首次发生梗死进行了大规模调查;迄今为止的结果看起来很有希望,尤其是在急性冠状动脉供血不足方面。虽然长期抗凝治疗存在非常现实的出血风险,但作者认为,只要严格注意禁忌症(如高血压)并确保对患者进行充分管控,出血很少会严重或致命。